LYRA
Lyra Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.33 / 10
Netural
Fund flow evaluation: 7.27/10 reflecting robust fund flow characteristics. Constructive overall, block, Large, and Extra-large trends face headwinds from adverse Small and Medium developments, indicating positive money flow direction. Analyst consensus points to divided analyst consensus with neutral perspective.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-14
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for LYRA?
- LYRA holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.33/10 (Netural).
